Spike Protein News and Research

RSS

ACE2 homology in laboratory and wild animals

A new preprint research paper posted to the bioRxiv server describes the conservation of an important receptor gene for the virus among several animal species that live in close contact or proximity to humans.

13 Apr 2021

Zipper motif mediates SARS-CoV-2 spike trimerization within host cell membrane

A new preprint research paper posted to the bioRxiv* server describes the results of a nuclear magnetic resonance (NMR) study to determine the structure of the S protein transmembrane domain (TMD) and its membrane-proximal regions.

13 Apr 2021

Nanobody cocktails neutralize SARS-CoV-2 and variants

Researchers report a collection of nanobodies derived from llamas, some of which can work synergistically and work against newer virus variants.

12 Apr 2021

Broadly cross-reactive antibody to SARS-CoV-2 RBD with robust resistance to mutational escape

A new study addresses an urgent need – namely, a therapeutic antibody directed specifically against a key SARS-CoV-2 antigen which is highly conserved among similar viruses, and is not easily bypassed by viral escape mutations.

12 Apr 2021

P681 mutation has little impact on transmissibility in the SARS-CoV-2 UK variant, finds study

A new preprint, recently released on the bioRxiv* server, explores the impact of a single mutation, the P681H mutation, on the transmissibility of the virus.

12 Apr 2021

Researchers provide ultrastructural details of SARS-CoV-2-infected respiratory epithelial cells

A team of scientists from the United Kingdom recently investigated the ultrastructural details of the attachment, entry, and budding processes of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in the human airway epithelium. They have used a highly differentiated air-liquid interface cultures of airway epithelium to thoroughly investigate the viral infection cycle. The study is currently available on the bioRxiv* preprint server.

12 Apr 2021

SARS-CoV-2 spike E484K mutation reduces antibody neutralization

Researchers at the Department of Microbiology, Icahn School of Medicine at Mount Sinai New York, USA, showed that the SARS-CoV-2 spike E484K mutation reduces antibody neutralization.

12 Apr 2021

Tapeworm infection drug blocks SARS-CoV-2 damage in the lungs

New research published in the journal Nature found the presence of SARS-CoV-2 in the lungs resulted in abnormal pneumocytes and spike protein-mediated cell fusion. Their findings also showed that TMEM16F protein activation induces cell fusion. Therefore, drugs inhibiting the TMEM16F/Anoctamin6 calcium-activated ion channel, such as niclosamide, could serve as potential treatments for reducing the severity of COVID-19 infection.

12 Apr 2021

Commercial assays detect mRNA-1273 and BNT162b2 vaccine-induced SARS-CoV-2 antibodies in most vaccinated participants

A recent study by researchers from Canada aimed to examine the ability of commercial assays to detect vaccine-induced antibodies and recognize the vaccination response.

12 Apr 2021

The role and ancestry of the SARS-CoV-2 spike protein glycan shield

In a research paper recently uploaded to the preprint server bioRxiv by Harbison et al. (April 1st 2021) a set of multi-microsecond long molecular dynamics simulations study the effects of altering glycosylation at sites N234, N165, N343, and the newly identified ancestral site N370, uncovering the influence of these sites on infectivity.

12 Apr 2021

Lung microbiome predicts COVID-19 disease severity

A new preprint research paper posted to the medRxiv* server found changes to the lung microbiome during severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection influence COVID-19 disease severity.

12 Apr 2021

L452R and Y453F SARS-CoV-2 mutations increase transmission and evade immunity

Mutations from the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have created multiple variants. Some variants, such as those found in South Africa and Brazil, have caused concern for their potential to evade the immune response. While vaccination efforts are underway, the world is racing against the viruses’ ability to evolve under selective pressure.

11 Apr 2021

Previously approved drugs starting points for COVID-19 therapeutics

Researchers in the United States have identified several clinically approved compounds that could be repurposed for the treatment and prevention of coronavirus disease 2019 (COVID-19).

11 Apr 2021

New polypeptide could provide universal protection against coronaviruses

Researchers in the United States have developed an inhibitor of the spike protein found on the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that limits its formation in host human cells that would otherwise be the source of newly generated virions.

11 Apr 2021

Tiny SARS-CoV-2 protein may have big implications for future COVID-19 treatments

A tiny protein of SARS-CoV-2, the coronavirus that gives rise to COVID-19, may have big implications for future treatments, according to a team of Penn State researchers.

9 Apr 2021

Study points to the involvement of Interleukin 33 in immunity to Sars-CoV-2

Since the beginning of the coronavirus pandemic, scientists and physicians worldwide undertook enormous efforts to understand the disease caused by the virus.

9 Apr 2021

Researchers discover a new monoclonal antibody that is effective against SARS-CoV-2 variants

A new monoclonal antibody targets a particular region of the RBD on the SARS-CoV-2. This region is usually not accessible to immune cells, which may be why it has broad neutralizing capabilities.

9 Apr 2021

Does natural infection with SARS-CoV-2 offer more protection than a vaccine against new variants?

A new study demonstrates that vaccines may be less effective at countering the newer SARS-CoV-2 variants compared to natural infection.

9 Apr 2021

Oxford-AstraZeneca COVID vaccine induces cell spikes similar to SARS-CoV-2's

Scientists from the University of Oxford and the University of Southampton report in the journal ACS Central Science that cells infected with the ChAdOx1 vaccine produce spike proteins on the cells similar to those produced by natural SARS-CoV-2 infection.

9 Apr 2021

Moderna COVID-19 vaccine ensures long-term protection against SARS-CoV-2 infection, suggests study

A recent report published in the New England Journal of Medicine has revealed that the COVID-19 vaccine developed by Moderna, Inc, USA, is capable of inducing robust and durable antibody responses for at least six months post-vaccination.

8 Apr 2021

Spike Protein News and Research

ACE2 homology in laboratory and wild animals

Zipper motif mediates SARS-CoV-2 spike trimerization within host cell membrane

Nanobody cocktails neutralize SARS-CoV-2 and variants

Broadly cross-reactive antibody to SARS-CoV-2 RBD with robust resistance to mutational escape

P681 mutation has little impact on transmissibility in the SARS-CoV-2 UK variant, finds study

Researchers provide ultrastructural details of SARS-CoV-2-infected respiratory epithelial cells

SARS-CoV-2 spike E484K mutation reduces antibody neutralization

Tapeworm infection drug blocks SARS-CoV-2 damage in the lungs

Commercial assays detect mRNA-1273 and BNT162b2 vaccine-induced SARS-CoV-2 antibodies in most vaccinated participants

The role and ancestry of the SARS-CoV-2 spike protein glycan shield

Lung microbiome predicts COVID-19 disease severity

L452R and Y453F SARS-CoV-2 mutations increase transmission and evade immunity

Previously approved drugs starting points for COVID-19 therapeutics

New polypeptide could provide universal protection against coronaviruses

Tiny SARS-CoV-2 protein may have big implications for future COVID-19 treatments

Study points to the involvement of Interleukin 33 in immunity to Sars-CoV-2

Researchers discover a new monoclonal antibody that is effective against SARS-CoV-2 variants

Does natural infection with SARS-CoV-2 offer more protection than a vaccine against new variants?

Oxford-AstraZeneca COVID vaccine induces cell spikes similar to SARS-CoV-2's

Moderna COVID-19 vaccine ensures long-term protection against SARS-CoV-2 infection, suggests study

Leveraging the power of automation to boost research

Automating research - solutions and best practices

How can microdialysis benefit drug development

Latest News